Crila and EGCG compositions for the treatment of uteral myeroma
Through the composition of southwestern Manjusura stem extract and EGCG, signaling pathways are adjusted and uterine fibroid cell proliferation is solved, and the side effects and high recurrence rate of existing treatment methods are solved, and the effective reduction of uterine fibroid size and recovery of fertility is achieved. The effect of ability.
Patent Information
- Application Number
- CN202380024783.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-01
- Filing Date
- 2023-02-28
- Publication Date
- 2024-11-29
AI Technical Summary
The existing treatments for uterine fibroids have problems with surgical risks, side effects and high recurrence rates, and pharmacological treatments are relatively ineffective and have adverse health effects.
Using a bioactive composition containing Southwest Manjusura dry extract and epigallocate gallate (EGCG), the size of uterine fibroids is reduced, symptoms are reduced, and fertility is restored by adjusting signaling pathways and inhibiting cell proliferation.
The composition significantly reduces the size of uterine fibroids, reduces related symptoms, reduces side effects, improves fertility, and is safe and does not require a long recovery period.
Smart Images

Figure CN119053334A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 315,101, filed on March 1, 2022, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present invention relates to biologically active compositions and preparations for treating uterine fibroids and diseases associated with intramural and submucosal fibroids, and combinations thereof. Background Art
[0004] Uterine leiomyomas (fibroids) affect 30-50% of women of childbearing age and are a significant cause of infertility. Intramural and submucosal fibroids reduce the likelihood of pregnancy compared to unaffected women (RR=0.3-0.7).
[0005] Surgical removal of uterine fibroids can restore fertility, however, the recurrence rate is very high, and the benefits are often temporary. Serious postoperative consequences such as adhesions usually have an adverse effect on women's fertility and health. Hysterectomy (i.e., surgical removal of the uterus) is the conventional treatment of uterine fibroids, and shows that up to one-third of all cases are applicable. Hysterectomy for the treatment of uterine fibroids may be very effective, but there are multiple undesirable side effects, such as loss of fertility, open surgery, sexual dysfunction and long recovery period. Hysterectomy treatment also has significant morbidity (e.g., sepsis, hemorrhage, peritonitis, intestinal and bladder damage), mortality and cost. Other access operations for the treatment of uterine fibroids include surgical myomectomy, such as laparoscopic myomectomy, hysteroscopic surgery (i.e., the process of imaging the inside of the uterus using a thin fiber optic camera), uterine artery embolization, endometrial resection, myolysis and needle myolysis.
[0006] Hormonal therapies that induce medical menopause can be used to reduce the size of uterine fibroids, but these therapies can also hinder pregnancy. Existing treatments for uterine fibroids include medical treatments using NSAIDS, estrogen-progesterone complexes, and GnRH analogs. Pharmacological treatments using GnRH analogs are limited by their side effects, such as hot flashes, vaginal dryness, mood changes, and bone density loss. Pharmacological treatments are relatively ineffective and have a palliative effect rather than a cure. U.S. Patent No. 10,155,004 discloses a method for administering estradiol-4,9-diene-3-one derivatives to treat diseases such as uterine fibroids of the uterus. U.S. Patent No. 5,472,977 discloses a method for inhibiting uterine fibroid diseases including administering various substituted triphenylpyran derivatives.
[0007] Crinum latifolium has a wide range of applications in folk and traditional medicine in Asia (Vietnam, Ayurveda, China) as a tonic and is used for inflammation, infection, allergic diseases and tumors. See Tram, NT Net al., Crinum L. (Amaryllidaceae). Fitoterapia 2002, 73 (3), 183-208; Gasca-Silva, CA et al., Recent updates on Crinum latifolium L. (Amaryllidaceae): A review of ethnobotanical, phytochemical, and biological properties. South African Journal of Botany 2022, 146, 162-173.
[0008] Several in vitro studies of Crinum latifolium have been published. See Jenny, M. et al., Crinum latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cells. Scientia pharmaceutica 2011, 79 (2), 323-336. One study showed that aqueous extracts had immunomodulatory properties in human peripheral blood mononuclear cells. See Zvetkova, E. et al., Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show immunomodulatory properties in human peripheral blood mononuclear cells. International immunopharmacology 2001, 1 (12), 2143-2150.
[0009] The plant has a long tradition of treating several ailments, including prostate problems in men and genital problems in women, but there is no data to confirm the ethnobotanical use of the herb. Of the 12 subspecies of the genus Crinum, established medicinal properties are associated with one subspecies, a specific species, Crinum latifolium L. var. crilae Tram & Khanh, which has become the focus of research over the past two decades. This species has been cultivated and propagated, and the processed plant material is now sold internationally under the trade name
[0010] Contains various phytochemicals such as clematis compounds and various types of amaryllis alkaloids. It has been shown to be useful for non-hormonal treatments that can reduce the size of uterine fibroids, relieve symptoms associated with uterine fibroids, and restore fertility in some cases. See Burton, TCEt al. In Examining the Estrogenicity of Crinum latifolium L. var. crilae Tram & Khanh, var n. (Amaryllidaceae) Using Cell-based and Receptor-based Assays, MENOPAUSE; The Journal of the North American Menopause Society, Lippincott Williams & Wilkins, 530 Walnut St. Philadelphia, PA 19106-3621 USA: 2014; pp 1335-1335.
[0011] Researchers have shown that in vivo, the growth rate of chemically induced tumors in rats was slowed after oral treatment with an aqueous extract of Crinum latifolium (L.) and Camellia sinensis. See Zvetkova, E. et al., Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show immunomodulatory properties in human peripheral blood mononuclear cells. International immunopharmacology 2001, 1 (12), 2143-2150. Acute toxicology studies in mice showed that no toxicity was detected for 48 hours at dose levels 20, 30, 80, and 100 times the usual human dose, or at daily doses of up to 25 gm / kg of dried extract of Crinum latifolium. LD 50 It is 49.7 gm / kg. See Yen, HT et al., The evaluation ofacute and subchronic toxicities of An Phu Khang capsules in experimentalanimals. Nghiên Y 2021, 148(12), 86-95. This finding of low toxicity has been confirmed in rats, rabbits and dogs, as well as in physiological models. See Zvetkova, E et al. above.
[0012] Standardized It was launched in Vietnam in 2005 and has recently been launched in other countries. In common use internationally, there have been no reports of adverse events requiring medical attention. The standard formulation has been sold in the United States since 2010.
[0013] use Clinical trials:
[0014] There are two well-described uterine fibroid tumors and benign prostatic hyperplasia (BPH). Clinical study. The BPH study was a single-arm open-label trial completed in 2005 at 3 hospitals in Vietnam with a total of 189 men participating for 2 months. Of the 157 completers, 89.2% demonstrated a beneficial response in the International Prostate Symptom Score (p<.001), a reduction in prostate volume (p<.05), and a reduction in residual urine volume (p<.05). Another 3-month study in 2007 successfully completed the study in 195 women with uterine fibroids (leiomyoma) at 3 hospitals. See Hoa, VT, To Evaluate the Effect and Possibility of Accepting of Crila in Uterus Fibroid Tumor Treatment. Vietnam Ministry of Health 2007.
[0015] Tumors were reduced in size or stopped growing in 79.5% of women, while in the rest of the women, tumors continued to grow slowly. The mean tumor diameter decreased from 48.5 mm to 44.4 mm (p < .01). Thirty-six percent of women reported The proportion of women with heavy menstrual flow before treatment decreased to 1% after treatment. There were no significant differences between baseline and study endpoint in vital signs, liver enzymes, creatinine and white blood cells. Red blood cells showed a slight increase within the normal range. No changes were found in microscopic urinalysis. Twenty patients (12.73%) experienced transient side effects that could be attributed to mild, mainly gastrointestinal reactions (17 subjects), dizziness (4), rash (2) and insomnia (1). In this open-label study of uterine fibroids (n=195, lasting 3 months), there were no changes in vital signs, liver and kidney function and blood cell counts from baseline to the last follow-up. The study was evaluated 3 times after baseline. Reported side effects included nausea, vomiting, headache, vaginal dryness and flushing. These side effects decreased with time and change in administration method and did not require medical intervention. 15% of women experienced mild nausea at the end of the first 30 days, but this number decreased to 5% at the end of 90 days. The report mentioned There was previous clinical work on the trial for uterine fibroids, but it was not described in detail. The preliminary work was done in 40 patients with uterine fibroids, and the results were cited as "satisfactory."
[0016] In 2005, the Vietnamese Ministry of Health approved The application is for men with benign prostatic hyperplasia (BPH) and is used in hospitals and pharmacies throughout Vietnam. In 2007, the Vietnamese Ministry of Health approved The application for women with uterine leiomyoma is used in hospitals and pharmacies across Vietnam.
[0017] Epigallocatechin gallate (EGCG):
[0018] Green tea leaves contain polyphenols such as catechins or flavin-3-ols, including epicatechin (EC), epigallocatechin (EGC), epigallocatechin gallate (EGCG) and alkaloids. See Singh, BNet al., Green teacatechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochemical pharmacology 2011, 82 (12), 1807-1821 and Zhang, Y. et al., A review for physiological activities of EGCG and the role in improving fertility in humans / mammals. Biomedicine & Pharmacotherapy 2020, 127, 110186. Catechins are the main component of tea-derived phenols, accounting for about 30-42% of the dry weight of green tea. Research indicates that EGCG catechin is the most abundant and active compound and is primarily responsible for the health-promoting effects of green tea and explains the favorable research results cited in the medical literature using green tea extracts. EGCG is the most abundant polyphenol and the primary antioxidant in green tea.
[0019] A study conducted by the U.S. Department of Agriculture reported that green tea has potential anti-tumor effects on a variety of human tumor cells, and EGCG inhibits key pathways of tumor growth. See Khan, N. et al., Tea polyphenols for health promotion. Life sciences 2007, 81 (7), 519-533. EGCG appears to block every stage of tumorigenesis by regulating signaling pathways involved in cell proliferation, transformation, inflammation, apoptosis, oxidative stress and invasion. EGCG polyphenols inhibit key pathways of tumor growth by regulating signaling pathways involved in cell proliferation, transformation, inflammation, apoptosis, metastasis and invasion. See Zhang, D. et al., Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nudemice. American Journal of Obstetrics and Gynecology 2010, 202 (3), 289.e1-289.e9.
[0020] Al-Hendy et al. have demonstrated that catechol-O-methyltransferase (COMT) levels are elevated in uterine leiomyomas compared to the adjacent myometrium and described its important role in the pathogenesis of uterine fibroids. Zhang, D.; Rajaratnam, V.; Al-Hendy, O.; Halder, S.; Al-Hendy, A., Green tea extractinhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecologic and obstetric investigation 2014, 78(2), 109-118. In addition, EGCG has been identified as a potential COMT inhibitor, which also contributes to its effective anti-uterine fibroid effect. See Zhang, D.; Al-Hendy, M.; Richard-Davis, G.; Montgomery-Rice, V.; Rajaratnam, V.; Al-Hendy, A., Antiproliferative and proapoptotic effects of epigallocatechingallate on human leiomyoma cells. Fertility and sterility 2010, 94 (5), 1887-1893. Zhang et al. have confirmed the effectiveness of EGCG in inhibiting the formation of uterine fibroids in nude mice. See Zhang, D. et al., American journal of obstetrics and gynecology 2010. Al-Hendy et al. also reported that EGCG acts as an anti-uterine fibroid agent by regulating multiple signal transduction pathways. The team further demonstrated that EGCG acts at the gene level to inhibit the proliferation of human uterine fibroid cells and induce apoptosis. This study also showed that in human uterine fibroid cells treated with EGCG, the expression of the BPM2 gene increased 14-fold compared to the untreated control group. The secretion of BMP2 in uterine fibroids treated with EGCG increased significantly, which may overcome the endometrial BMP resistance caused by uterine fibroids by increasing the binding to BMP receptors, improve endometrial decidualization, and subsequently enhance implantation ability, fertility and pregnancy outcomes. In addition, the study also showed that EGCG significantly reduced the production of TGF-β3 in human uterine fibroid cells.See Ciebiera, M. et al.; Role of transforming growth factor β in uterine fibroid biology. International Journal of Molecular Sciences 2017, 18(11), 2435. Since TGF-β3 is the main cytokine that causes endometrial BMP resistance, this effect of EGCG is expected to improve the receptivity of the endometrium.
[0021] The above examples and limitations of the related art are for illustration only and are not exclusive. After reading this specification and studying the figures or drawings provided herein, those skilled in the art will find other limitations of the related art. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 yes Representative chromatograms showing the major components.
[0023] Figure 2 yes Figure 1 A partial enlargement and labeling of a representative chromatogram, where the major peaks and their retention times are labeled in order. A , B , C , D , E , F , G , H , I , J and K . Summary of the invention
[0024] As disclosed herein, the inventors have recognized that there is a continuing need for effective, non-hormonal, non-surgical, fertility-friendly treatment options for uterine fibroids and related disorders.
[0025] The following embodiments, aspects, and variations thereof are exemplary and illustrative and are not intended to be limiting in scope.
[0026] In one embodiment, the present application discloses novel and biologically effective compositions and formulations, and methods for their use in treating uterine fibroids.
[0027] In one embodiment, the present application discloses a method comprising a dry extract of Crinum suffruticosa and epigallocatechin gallate (EGCG), wherein the composition The ratio of EGCG ranges from 1:10 wt / wt to 100:1 wt / wt. In one variation, the composition The ratio of EGCG ranges from 10:1 wt / wt to 1:100 wt / wt. In another variation, the composition In another embodiment, the ratio of EGCG to EGCG is 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:40, 1:30, 1:20 or 1:10 wt / wt. The ratio of is 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:40, 1:30, 1:20 or 1:10 wt / wt. In one variation, the therapeutically active composition is a pharmaceutical composition. As used herein, The ratio of EGCG is specified as wt / wt. The weight to weight ratio of EGCG can be expressed in milligrams, such as mg / mg, or in grams, such as g / g (or gm / gm). As used herein, the term "dry extract" refers to a dry extract obtained from The components or mixtures of extracts obtained from the extracts and, as defined herein, may be formulated as single components or mixtures of specific isolated components (or compounds or alkaloids), as disclosed herein composition; or the term may include all components, including All alkaloids and other compounds obtained in the extract.
[0028] In another embodiment, there is provided an isolated The therapeutically active composition of compositions 1 to 20. As described herein, the therapeutically active composition comprises a dry extract of Crinum juncea, which may be or containing the separation mixture listed in Table 1 composition. Thus, for example, Composition 1 (Table 1) comprises the components A , B , C , D , E , F , G , H , I , J and K ; Composition 2 (Table 1) comprises the components A and B ; Composition 8 (Table 1) comprises the components D , E ,F , G and H In one aspect, the composition comprises isolated A composition selected from the group consisting of: comprising components A , B , C , D , E , F , G , H , I , J and K of Composition 1; comprising components A and B of Composition 2; comprising components A , B and C of Composition 3; comprising components A , B , C and D of Composition 4; comprising components A and C of Composition 5; comprising components A , C and D of Composition 6; comprising components A , B , G and H of Composition 7; comprising components D , E , F , G and H of Composition 8; comprising components A , D , E , F , G and H of Composition 9; comprising components A , F , G and H of Composition 10; comprising components A , B , C , I , J andK of Composition 11; comprising components C , D , E and F of Composition 12; comprising components C , D , E , F , G , H and I of Composition 13; comprising components D , E and F of Composition 14; comprising components D , E , F , G and H of Composition 15; comprising components A , D , E and F of Composition 16; comprising components C , D , G , H and I of Composition 17; comprising components D , E , F , J and K of Composition 18; comprising components A , B , C , D , E , F and G of Composition 19; and comprising components E , F , G and H of Composition 20.
[0029] In one aspect of the above composition, the composition The ratio of EGCG ranges from 1:1wt / wt to 10:1wt / wt. In another aspect of the composition, the composition The ratio of EGCG ranges from 1:1 wt / wt to 5:1 wt / wt. The ratio of EGCG ranges from 4.0:1wt / wt to 5.5:1wt / wt. In another aspect of the above composition, and EGCG are formulated into dry powder. In yet another aspect, and EGCG are formulated in a capsule preparation or capsule dosage form.
[0030] In one variation of the above composition, the capsule is a soft capsule. In another variation, the capsule is a hard capsule. In another variation, the capsule is an enteric-coated capsule, such as a capsule prepared from cellulose derivatives such as HPMC AS-LF and HP-55 and acrylic acid / methacrylic acid derivatives of acrylic resins L100 and S100, in the presence or absence of a plasticizer.
[0031] In another embodiment of the present application, a pharmaceutical composition containing the above therapeutically active composition is provided, wherein the therapeutically active composition comprises a dry extract of Crinum suffruticosa and epigallocatechin gallate (EGCG, >95% purity); and a pharmaceutically acceptable excipient, wherein the composition is effective for treating intramural fibroids or subserosal fibroids (uterine leiomyoma).
[0032] In another embodiment, the present application discloses a method for treating, preventing, slowing progression, and reversing one or more symptoms of intramural fibroids or subserosal fibroids (uterine leiomyoma) in a subject or a subject at risk of having one of the intramural fibroids or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject daily a therapeutically active composition comprising a dry extract of Crinum cyrtonema and epigallocatechin gallate (EGCG), wherein the ratio of the southwestern crinum dry extract to the EGCG in the composition ranges from 1:10wt / wt to 100:1wt / wt, so as to prevent, slow down the progression and / or arrest intramural fibroids or subserosal fibroids.
[0033] In one variation, the present application discloses a composition containing a dry extract of Crinum suffruticosa L. and epigallocatechin gallate (EGCG), wherein the ratio of the dry extract of Crinum chinense to EGCG in the composition ranges from 1:10wt / wt to 100:1wt / wt, for treating intramural fibroids or subserosal fibroids (uterine leiomyoma) in a subject in need thereof. In another variant, the present application discloses a composition containing A composition of a mixture of a dry extract of Crinum chinense and EGCG, wherein the ratio of the dry extract of Crinum chinense to EGCG ranges from 1:10wt / wt to 100:1wt / wt, for use as a medicament for treating intramural fibroids or subserosal fibroids (uterine leiomyoma) in a subject in need thereof.
[0034] In one aspect of the above method, the composition The ratio of EGCG ranges from 1:1 wt / wt to 10:1 wt / wt. The ratio of EGCG ranges from 1:1 wt / wt to 5:1 wt / wt. In another aspect of the method, the composition The ratio of EGCG ranges from 4.0:1wt / wt to 5.5:1wt / wt. In another aspect, the composition and EGCG are formulated into dry powder. In another aspect of the above method, and EGCG are formulated in a capsule preparation or capsule dosage form.
[0035] In another embodiment, a method of treating cancer in a patient is provided, the method comprising administering to the patient a therapeutically effective amount of a composition comprising an isolated Composition, isolated The composition is selected from the group consisting of: comprising components A , B , C , D , E , F , G , H , I , J and K of Composition 1; comprising components A and B of Composition 2; comprising components A , B and C of Composition 3; comprising components A , B , C and D of Composition 4; comprising components A and C of Composition 5; comprising components A , C and D of Composition 6; comprising components A ,B , G and H of Composition 7; comprising components D , E , F , G and H of Composition 8; comprising components A , D , E , F , G and H of Composition 9; comprising components A , F , G and H of Composition 10; comprising components A , B , C , I , J and K of Composition 11; comprising components C , D , E and F of Composition 12; comprising components C , D , E , F , G , H and I of Composition 13; comprising components D , E and F of Composition 14; comprising components D , E , F , G and H of Composition 15; comprising components A , D , E and F of Composition 16; comprising components C , D , G , H and I of Composition 17; comprising components D , E, F , J and K of Composition 18; comprising components A , B , C , D , E , F and G of Composition 19; and comprising components E , F , G and H of Composition 20, to a patient in need of such treatment. In another aspect of the method, the cancer is selected from the group consisting of leukemia, neuroblastoma, glioblastoma, cervical cancer, colorectal cancer, pancreatic cancer, renal cancer and melanoma. In another aspect of the method, the cancer is selected from the group consisting of lung cancer, breast cancer, prostate cancer, ovarian cancer and head and neck cancer.
[0036] The disclosed compositions respectively comprise and EGCG, or a composition containing and EGCG, or The composition may include a solubility enhancer or cosolvent selected from oleic acid, EL (polyethylene glycol castor oil or castor oil polyoxyethylene ether), vitamin E TPGS (D-α-tocopheryl polyethylene glycol-1000 succinate), CC (glyceryl monolinoleate), 44 / 14 (lauroyl macrogol-32 glyceryl), 812N (esters of caprylic fatty acids and glycerol derived from saturated coconut and palm kernel oils), Oleique (polyglyceryl-6 dioleate), Lauroglycol TM 90(propylene glycol laurate (type II)), (Glyceryl Caprylate Macrogol-8 Glycerides), EL (polyethylene glycol castor oil), (SBE-β-cyclodextrin), Peceol TM (Glycerol / glycerol monooleate (type 40)), sodium deoxycholate, deoxycholic acid, M2125CS (linoleoyl macrogol-6 glyceride).
[0037] In one variation, or The dosage of the composition is 50 mg to 5,000 mg per day, and the dosage of EGCG is 50 mg to 1,000 mg per day. In another variant, the dosage of the composition is 100 mg to 7,000 mg per day. In one variant, the composition is applied daily or every other day for at least 30, 60, 90 or 120 consecutive days. In another variant, the composition is applied for at least 1 month, 2 months, 3 months, 4 months, 5 months or 6 months in a row.
[0038] In another embodiment, the present application discloses a pharmaceutical composition containing a therapeutically effective amount of a composition, wherein the composition comprises the dry extract of Crinum suffruticosa of any of the above embodiments and aspects. A mixture of epigallocatechin gallate (EGCG), or a mixture thereof; and a pharmaceutically acceptable excipient, wherein the composition is effective for the treatment of uterine fibroids; and conditions associated with intramural fibroids or subserosal fibroids (uterine leiomyoma) and methods for treating uterine fibroids.
[0039] In one variation of the above composition, the composition is a nutraceutical composition, a dietary supplement or a pharmaceutical composition. A nutraceutical composition is considered a substance or composition that is a food or a portion of a food and is believed to provide a medical benefit or health benefit and can help prevent or treat one or more diseases.
[0040] In another embodiment, a method of treating intramural or subserosal fibroids in a subject in need thereof is provided, the method comprising administering to the subject a therapeutically active composition comprising a dry extract of Crinum chinense and epigallocatechin gallate (EGCG), wherein the ratio of the dry extract of Crinum juncea to EGCG in the composition ranges from 1:10wt / wt to 100:1wt / wt.
[0041] In another embodiment, a method is provided for treating, preventing, slowing progression, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyoma) in a subject or a subject at risk of having one of the intramural or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject a therapeutically active composition comprising a dry extract of Crinum cyrtonema and epigallocatechin gallate (EGCG), wherein the ratio of the southwestern crinum dry extract to EGCG in the composition ranges from 1:10wt / wt to 100:1wt / wt, so as to prevent, slow down the progression and / or inhibit intramural fibroids or subserosal fibroids.
[0042] In one aspect of the above method, applying the dry extract of Crinum chinense and epigallocatechin gallate (EGCG), wherein the ratio of the southwestern crinum dry extract to the EGCG in the composition ranges from 1:10wt / wt to 100:1wt / wt, and wherein the administration is and concomitant administration of EGCG.
[0043] As used herein, Concomitant administration of EGCG and EGCG refers to administering or giving EGCG to a patient at the same time or nearly at the same time. and EGCG, as in EGCG was given after or after EGCG Or on the same day EGCG was given after or on the same day after EGCG
[0044] In another aspect of the above method, The dosage of EGCG is 920 mgs, BID (i.e., twice a day), two capsules each time, equivalent to 3680 mgs per day, for 90 days, and the dosage of EGCG is 400 mgs, twice a day, one capsule each time, equivalent to 800 mgs per day, for 90 days. In another aspect of the method, the dosage of EGCG is 150 mgs, twice a day, one capsule each time, equivalent to 300 mgs per day and The dosage is 920 mgs, twice a day, two capsules each time, equivalent to 3680 mgs per day, for 90 days. In another aspect of the method, the dosage of EGCG is 150 mgs, twice a day, one capsule each time, a combined dose, and The dosage is 920 mgs, two capsules twice daily, equivalent to a combined daily dose of 3680 mg for 90 days.
[0045] In another aspect of the above method, The dosage of EGCG is 50 mg to 1,000 mg per day, and the dosage of EGCG is 50 mg to 1,000 mg per day. The composition of EGCG is administered daily for at least 30, 60, 90 or 120 consecutive days.
[0046] The above embodiments, aspects and variants also include salts of amino acids such as arginate, gluconate and galacturonate. A pharmaceutical composition is also provided, comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of the composition.
[0047] The pharmaceutical composition of the present invention can be formulated into a powder such as a lyophilized powder for oral or parenteral administration. The powder can be reconstituted by adding a suitable diluent or other pharmaceutically acceptable carrier before use. Liquid preparations are usually buffered, isotonic aqueous solutions. Examples of suitable diluents include physiological saline solutions, 5% glucose aqueous solutions, or sodium acetate buffer or ammonium acetate buffer. This dosage form is particularly suitable for parenteral administration, but can also be used for oral administration. Excipients such as polyvinyl pyrrolidone, gelatin, hydroxycellulose, gum arabic, polyethylene glycol, mannitol, sodium chloride or sodium citrate can also be added. Alternatively, these compounds can be made into capsules (encapsulated), tablets or into emulsions or syrups for oral administration. Pharmaceutically acceptable solid or liquid carriers can be added to enhance or stabilize the composition, or to make the composition easier to prepare. Liquid carriers include syrups, peanut oil, olive oil, glycerol, saline, alcohols or water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, gypsum powder, magnesium stearate or stearic acid, talc, pectin, gum arabic, agar, silicon dioxide or gelatin. The carrier may also include a sustained release material, such as glyceryl monostearate or glyceryl distearate, used alone or mixed with a wax. The amount of solid carrier varies, but each dosage unit may be between about 20 mg and 1 g. The pharmaceutical preparation is prepared according to the following conventional pharmaceutical techniques, for tablet dosage forms, grinding, mixing, granulating and tableting are performed as necessary; or for hard gelatin capsule dosage forms, grinding, mixing and filling are performed. When a liquid carrier is used, it is prepared in the form of a syrup, elixir, emulsion, or aqueous or non-aqueous suspension. This liquid preparation can be directly orally administered or filled into a soft gelatin capsule for administration.
[0048] In one aspect, the disclosed compositions are formulated into capsules, such as gel capsules. In particular applications, the capsules are hard capsules, wherein the capsule shell may include gelatin, hydrolyzed starch, or a cellulose derivative such as hydroxypropylmethylcellulose (hydroxypropyl methylcellulose). In one variation, the capsule includes a plurality of microparticles and one or more pharmaceutically acceptable excipients. The excipient may be selected from a gelling polymer, a filler, an effervescent system, a glidant, an ion exchange resin powder, or a combination thereof; or as disclosed herein. In one variation, the capsule may include one or more excipients. In one variation, the capsule may include one or more gelling polymers, wherein the gelling polymer is a hydrophilic gelling polymer that absorbs water or a solvent and / or swells to form a viscous mixture or a gel. Examples of suitable hydrophilic gel polymers include cellulose ethers (e.g., hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, etc. ...), polyolefin oxides (e.g., polyethylene oxide, polypropylene oxide, etc. ...), natural gums (e.g., glucomannan, guar gum, gum arabic, gum tragacanth, tara gum, alginate, alginic acid, fucoidan, laminarin, agar, carrageenans, xanthan gum, gellan gum, dextran, welan gum, diutan gum, pullulan, etc. ...), polyacrylic acid or cross-linked polyacrylic acid (e.g., carbomer), polyvinyl alcohol, polyvinyl pyrrolidone, polyamines, or combinations of gel polymers. The average molecular weight of the gel polymer may range from about 30,000 to about 15,000,000. When a gelling polymer is used in the capsule, the amount of gelling polymer can range from about 0.1% to about 50% by weight of the capsule contents; or from about 0.1% to 10%, about 10% to 20%, about 20% to 30%, about 30% to 40%, or about 40% to 50% by weight of the capsule contents.
[0049] In another variation, the capsule further includes one or more fillers or diluents. Suitable fillers may include cellulose, microcrystalline cellulose, cellulose derivatives (e.g., calcium carboxymethylcellulose, ethyl cellulose), starch (e.g., potato starch), modified starch, pregelatinized starch, glucose / dextrose, fructose, sucrose, lactose, mannitol, sorbitol, xylitol, calcium carbonate, calcium sulfate, calcium phosphate, calcium silicate, magnesium carbonate, magnesium oxide, or a combination thereof. The amount of filler may range from about 0.1% to about 50% by weight of the capsule contents; or from about 0.1% to 10%, about 10% to 20%, about 20% to 30%, about 30% to 40%, or about 40% to 50% by weight of the capsule contents.
[0050] Suitable formulations can be found for each method of administration, for example in Remington: The Science and Practice of Pharmacy, A. Gennaro, ed., 20th edition, Lippincott, Williams & Wilkins, Philadelphia, Pa.
[0051] In addition to the exemplary embodiments, aspects and variations described above, further embodiments, aspects and variations will become apparent by reference to the drawings and figures, and by study of the following descriptions. DETAILED DESCRIPTION
[0052] definition:
[0053] Unless otherwise specifically stated herein, the definitions of terms used are standard definitions in the fields of organic synthesis and pharmaceutical sciences. Exemplary embodiments, aspects, and variations are illustrated in the accompanying drawings and figures, and the embodiments, aspects, and variations disclosed herein and the accompanying drawings and figures are intended to be considered illustrative rather than limiting.
[0054] "Pharmaceutically acceptable salts" refer to salt compositions that are generally considered to have the desired pharmacological activity, are considered safe, non-toxic, and can be used in veterinary and human medicine. Such salts include acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, etc.; or with acetic acid, propionic acid, caproic acid, malonic acid, succinic acid, malic acid, citric acid, gluconic acid, salicylic acid, etc.
[0055] "Therapeutically effective amount" refers to the amount of a compound or drug that can elicit any of the biological effects listed in this specification.
[0056] Experimental:
[0057] The following steps can be used to prepare the composition of the present invention. The composition comprises The active ingredients of the powder and Selected and separated components and mixtures of components in powders.
[0058] powder:
[0059] The invention comprises a dry plant extract of a cultivated variety of the Amaryllidaceae family, Crinum latifolium Lvar.crilae Tram & Khanh. The dry plant extract can be obtained from varieties cultivated in various ways.
[0060] For example, leaves of living plants are picked at the desired time for the age and size of the cultivar to optimize the amount and ratio of the active ingredient. Depending on the growing environment and weather conditions, the leaves of the plants are usually harvested every 2-3 years. In one method, the leaves are collected and rinsed with water to remove dirt and foreign matter. In a variant, the leaves are dried and dried in full sunlight for at least 24 to 48 hours to reduce the water content. Alternatively, the leaves are placed in a withering tray and warm air (about 45°C) is passed over the leaves for a period of time to provide dry leaves with the desired moisture content, usually less than about 5% moisture content; or leaves with a moisture content of less than 5%. The moisture content can be determined using the Karl-Fischer (KF) method or other standard methods well known in the art. The dried leaves can be stored in a dry, dark storage room for up to one to two years.
[0061] Fermentation and extraction steps:
[0062] About an equal weight of water is added to the dry leaves, and the slurry is allowed to stand for 3 hours. The resulting slurry is repeatedly gently pressed or rolled with a roller for at least 3 hours to break up the cells of the leaves and allow the chemical components to mix together. The rolling of the leaves can be carried out at room temperature or at a temperature of about 40°C or lower for a desired time, such as 6 to 12 hours or up to about 48 hours.
[0063] The resulting aqueous leaf slurry is warmed to about 45 to 50°C and agitated for at least 6 to 12 hours to allow the active substances in the solution to mix and produce a "fermentation process". The slurry is further subjected to an extraction treatment using a solvent or solvent mixture, such as water, or a mixture of water and an alcohol, such as ethanol. The mixture of water and ethanol can be 10% ethanol in water, 20% ethanol in water, 30% ethanol in water, or about 40% ethanol in water. The resulting water-ethanol slurry is then stirred for at least 3 hours, from about 3 hours to 12 hours, or up to about 24-30 hours to extract the active ingredients from the slurry containing leaves and leaf fragments. The length of time used for the extraction step will depend to some extent on the water-alcohol ratio and the amount of aqueous slurry being treated.
[0064] Alternatively, the Southwestern Crinum plant (or leaf) extract can be obtained by an extraction step using an organic solvent selected from the group consisting of ethanol, methanol, ether, ethyl acetate, methyl acetate, acetone, MTBE, MEK, ethylene glycol, hexane, heptane, chloroform, dichloromethane or a mixture thereof. In another variant, the Southwestern Crinum extract can be obtained by an extraction step using a composition of hot water (about 45°C to 90°C) and ethanol. In another variant, the Southwestern Crinum extract can be obtained by an extraction step using water and an organic solvent or solvent mixture as exemplified above. In one variant, the extraction solvent can be selected from warm water at about 50°C to 60°C; such as solvent mixtures of ethyl acetate and water, ethyl acetate and methanol, and ethyl acetate and hexane.
[0065] When a solvent mixture is used in the extraction step, the more polar solvent in the solvent mixture may be increased over time during the extraction step. For example, when a solvent mixture such as ethyl acetate and methanol is used during the extraction step, the initial solvent mixture may be ethyl acetate containing about 5% methanol, and the amount of methanol may be gradually increased over time, such as in a second or subsequent extraction step. The increase in the amount of methanol may be, for example, from 5% methanol in ethyl acetate, to 10% methanol, to 20% methanol, to 30% methanol, to 40% methanol, to 50% methanol, to 60% methanol, to 70% methanol, to 80% methanol, and then to 90% methanol in ethyl acetate. Alternatively, extraction may be performed using supercritical extraction with liquid CO2, which is well known in the art.
[0066] The slurry is then filtered or strained to remove large pulp fibers, either through a stainless steel 28 or 38 mesh screen, a 28 or 38 mesh basket filter, or through a 28 or 38 mesh inline filter. The filtrate is stirred for about 3 hours and then transferred to a low pressure still to distill water and ethanol under reduced pressure at a temperature of about 45° C. The resulting brown-green slurry is transferred to a storage tank, and potato starch and silica chunks are optionally added to the slurry and stirred for about 3 hours.
[0067] Isolation by spray drying:
[0068] The resulting slurry is spray dried using standard parameters known in the art, for example using a spray dryer with a pressure nozzle. The concentration of the plant slurry can be 10-15% or up to 25% of the dry matter content. The inlet temperature, feed temperature and pump speed for spray drying are selected to be between 100 and 150°C, 5 and 30°C, and 20 to 40% (50 L / h to 100 L / h), respectively. The spray dried material is removed from the spray dryer and then stored in a dry holding tank and then subjected to quality control analysis. Once the product passes the required quality standards, The powder is then encapsulated or bottled.
[0069] Figure 1 (Attached Figure 1 ) is analyzed by LC / MS / MS / MS method and prepared into dry Representative spectra of powder samples using a Thermo TSQ Vantage Triple Stage Quadrupole LC / MS / MS / MS system, which uses a Thermo Finnigan TSQ Vantage with a HESI II Source (equipped with two mechanical pumps) and an Xcalibur data system to provide optimal measurement precision and accuracy. The TSQ Vantage is equipped with an electron source, second generation (G2) electron optics, and a hyperbolic quadrupole to provide high sensitivity with low chemical noise. The spectrum is shown as a full-time trace from the LC / MS / MS / MS. The chromatogram shows the results of the scan data. The second figure is the EIC method developed using an internal standard. Separation was performed using a 0.5 x 50 mm, Targa C-18AQ column with a flow rate of 40 μls / min.
[0070] Figure 2 (Attached Figure 2 )yes Figure 1 A magnified region of the spectrum shows The separation and assignment of the various major components of a spectrum are performed by identifying peaks labeled with retention times (RT, in minutes) in specific regions of the spectrum. A arrive K ) are respectively A (7.15), B (7.63), C (7.65), D (8.40), E (8.57), F (8.76), G (8.91), H (9.10), I (9.63), J (9.85) and K (9.97). As observed in the chromatogram, the peaks are designed as C (7.65), there is at least a second unresolved component (or peak) when the RT is 7.66.
[0071] from The major alkaloid components identified in the extract include lycorine, crinamidine, flexinine, ambellin, ambellin epoxy, triperidine, 11,12-dehydroanhydro bowdensine, 6α-deoxy-8-oxo-macronin, 1-epidemethybowdensine, lycobetaine, crinamidine, crinamidamine or 8-O-demethyl-homolycorine, norgalantamine, homolycorine, cripowellin B, lycorine dimer, flexinine, and 1-O-acetyllycorine. See Nguyen Thi Ngoc Tram et al, Fitoterapia, 2002 Jun; 73(3); 183-208 and Silva, LC et al, Molecules, 2002, May 6; 27(9); 2976. LC / MS chromatograms of the compositions were used to separate the various alkaloid components and identify the alkaloids and alkaloid mixtures associated with the different fractions, which could be separated and collected for biological evaluation.
[0072] Figure 3 (Attached Figure 3 ) is a representative diagram showing that the peak extracted from the mixed solution is quantitatively crinidine, showing the complete MS data information and confirmation ions from the crinidine molecule. The system shows the transmission of MW 318.156, which is the single-charged ion MW+H of crinidine with an accurate mass of 317.1257742Da. Since the system is a triple quadrupole system, rather than an accurate mass system, it is observed that it has a slight difference from the true calculated mass. The daughter ions produced after passing through the collision cell seem to represent the loss of C2H3O, or the fragmentation of the ring, resulting in the monitored ion MW of 272.099-272.101Da. Typically, the analysis and identification of daughter ions is achieved by injecting the parent molecule directly into the solution and then optimizing the energy and collision cell parameters to produce fragments of the parent molecule. After identifying the potential monitoring ions, a method can be created to analyze complex samples to identify the transition ions with the least interference and the best overall signal, which are then used as quantitative / qualitative ion selection for the method validation series.
[0073] The liquid chromatography (LC) gradient program for different solvent systems containing formic acid used water (H2O), methanol (MeOH) containing 0.1% formic acid, as shown in the table below.
[0074]
[0075] For the treatment of uterine fibroids Alkaloid components:
[0076] The samples were analyzed using the Thermo TSQ Vantage Triple Stage Quadrupole LC / MS / MS / MS system. Based on the results obtained by the spectrometer, the results can be used for preparative-scale HPLC, which can be used for scale-up and preparative-scale An optimal method was designed for the separation of the above identified components. The separated fractions among the obtained components were identified as A (7.15), B (7.63), C (7.65), D (8.40), E (8.57), F (8.76), G (8.91), H (9.10), I (9.63), J (9.85) and K (9.97), and their various mixtures (“ Compositions Nos. 1 to 20), as summarized in Table 1 below, have been prepared and the volatile solvent removed by freeze drying or lyophilization to obtain an alkaloid residue or a mixture of alkaloid residues (also referred to as " Dry extract”) was used for biological evaluation.
[0077] Table 1
[0078]
[0079] As mentioned above, the name of a particular composition, i.e. " Composition" (also as described in the table above), if defined as a component C (7.65) may include, for example, one or more alkaloids or other The natural product compounds mentioned above Compositions constitute a subset of botanical compositions, medicaments or complex mixtures that may lack a clear active ingredient and are derived from natural products, i.e. It is obtained from and includes a variety of plant ingredients.
[0080] Separate Cytotoxicity of the composition:
[0081] MTS proliferation assay using SK-N-AS cells
[0082] Day 1: SK-N-AS cells were plated at 5x10 3 Each well was inoculated with 100 μL of the appropriate culture medium in a 96-well tissue culture plate (Falcon). Sample or Each composition sample uses a separate plate. The first column is blank; it contains culture medium and no cells. The plates are incubated overnight at 37°C, 5% CO2 to allow attachment.
[0083] Day 2: or The composition was diluted with culture medium and added to cells at a concentration of 0.005 nM to 10 μM, and each concentration was repeated 4 times. or After 48-72 hours of exposure to the composition, depending on the cell type, Aqueous Non-Radioactive Cell Proliferation Assay (MTS), Nutritional Drug (Promega), add MTS reagent to all wells and incubate for 1-6 hours (37°C, 5% CO2). The culture plate was measured at a wavelength of 490 nm using a Bio-Tek Synergy HT multi-function microplate reader, and the data was processed using KC4V.3 software. or The data of the comparison between the concentration and absorbance of the combination is inferred for each detection (separation) or The 50% inhibition concentration (IC 50 ).
[0084] For the treatment of uterine fibroids or Composition and EGCG:
[0085] or Effects of the composition (Table 1) and / or EGCG on the growth of uterine fibroids: In one study, we investigated Human leiomyoma (HuLM) cells were used for preliminary evaluations of EGCG and / or EGCG treatment. Or used in combination with EGCG, the ability to inhibit the proliferation of HuLM cells was evaluated by the following experimental method. The ability of the composition to inhibit the proliferation of HuLM cells was evaluated by the following experimental method.
[0086] Effects of single or combined treatments on HuLM cell growth:
[0087] Analyzed at various concentrations and indicated time points and / or EGCG.
[0088] alone
[0089]
[0090]
[0091] As shown in the figure above, When used alone at concentrations from 1000 μg / ml or higher It effectively reduced the viability of HuLM cells, but only after 5 and 7 days of treatment, with IC50 of 971.5±223.9μg / ml and 902.5±76.2μg / ml, respectively. The inhibitory effect observed on day 5 was statistically significant (*p value < 0.05, **p < 0.01).
[0092] EGCG alone
[0093] 1, 3, 5, 7 days EGCG 0μM EGCG 10μM EGCG 25μM EGCG 50μM EGCG 100μM EGCG 200μM
[0094]
[0095] As shown in the figure above, EGCG alone effectively reduced the viability of HuLM cells after 5 days of treatment and at EGCG concentrations from 50μM and higher, and after 7 days of treatment and at EGCG concentrations from 25μM and higher. At these doses, the inhibitory effects observed on days 5 and 7 were statistically significant (*p value < 0.05, ****p < 0.0001).
[0096] Because the simultaneous use of both agents on the first day resulted in inconsistent data, we decided to focus on treatments on days 2, 3, 5, and 7 for the studies described below in which cells were treated with the combination of drugs. The design and results of combined EGCG treatment are shown below.
[0097] Combined with EGCG
[0098] 2, 3, 5 and 7 days EGCG+Crila 50μM+0μg / ml EGCG+Crila 50μM+100μg / ml EGCG+Crila 50μM+250μg / ml EGCG+Crila 50μM+500μg / ml EGCG+Crila 50μM+1000μg / ml
[0099]
[0100] As shown in the figure above, after 3, 5, and 7 days of treatment, the Compared with the treatment (white bars), when combined with 50 μM EGCG (shaded bars), all concentrations tested All of them showed that they could effectively reduce the survival rate of HuLM cells. At these doses, starting from day 3 and continuing to day 7, statistically significant inhibitory effects of combined EGCG were observed (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, respectively). These experiments were repeated twice.
[0101] The results have shown that when Combining EGCG and treating HuLM cells at a concentration of 100-1000 μg / ml for 3-7 days showed a stronger inhibitory effect. These effects were seen at a minimum concentration of 100 μg / ml.
[0102] Likewise, The ability of the composition to inhibit the proliferation of HuLM cells was evaluated by the experimental method described above, and when After the composition was combined with EGCG, HuLM cells were treated at a concentration of 100-1000 μg / ml for 3-7 days, showing a stronger inhibitory effect.
[0103] or Synergistic inhibitory effect of the composition and EGCG on HuLM cell growth:
[0104] For further exploration To determine whether there is a synergistic effect of combined EGCG treatment on HuLM cells, based on the above studies, we focused on the following studies in which EGCG was 10, 25, and 50 μM and the treatment was for 3, 5, and 7 days. The design and results of combined EGCG treatment are shown below.
[0105] 3, 5, 7 days Crila+EGCG 0μg / ml+0μM Crila+EGCG 100μg / ml+10μM Crila+EGCG 250μg / ml+10μM Crila+EGCG 500μg / ml+10μM Crila+EGCG 1000μg / ml+10μM Crila+EGCG 100μg / ml+25μM Crila+EGCG 250μg / ml+25μM Crila+EGCG 500μg / ml+25μM Crila+EGCG 1000μg / ml+25μM Crila+EGCG 100μg / ml+50μM Crila+EGCG 250μg / ml+50μM Crila+EGCG 500μg / ml+50μM Crila+EGCG 1000μg / ml+50μM
[0106]
[0107] As shown in the figure above, when Combined with 25 and 50 μM EGCG, all measured concentrations, all showed a synergistic inhibitory effect on the survival rate of HuLM cells. Combined with 10 μM EGCG, the The concentrations of 500 μg / ml did not produce a sustained synergistic inhibitory effect on the growth of HuLM cells, especially in point 3 (500 μg / ml The opposite effect was observed in combination with 10 μM EGCG. These experiments were repeated twice.
[0108] We infer The combination of Crila and EGCG can show a synergistic inhibitory effect when HuLM cells are treated with 100-1000 μg / ml Crila and 25-50 μM EGCG for 3-7 days. These effects were not sustained when combined with 10 μM EGCG.
[0109] Likewise, when When the composition is combined with EGCG, HuLM cells are treated with 10, 25 and 50 μM EGCG for 3 days, 5 days and 7 days, which can produce a synergistic effect.
[0110] Crila and EGCG treatment inhibited HuLM cell growth by reducing proliferation rather than increasing apoptosis:
[0111] Based on the determined concentrations of the combined reagents, we simultaneously performed mRNA and protein level analyses using qRT-PCR and western blotting, respectively, to assess whether the inhibition of HuLM cell growth was caused by the inhibition of proliferation markers such as PCNA or the pro-apoptotic marker BAX, or both.
[0112]
[0113]
[0114] As shown in the real-time RT-PCR results in the above figures, when combined with 50 μM EGCG, the use of 100 to 500 μg / ml The level of PCNA mRNA, a proliferation marker, was significantly decreased, but the effect reached a plateau at this time, because it was different from that of 1000 μg / ml alone. Compared with 1000 μg / ml Combination with 50 μM EGCG did not result in a significant decrease in PCNA expression.
[0115] Real-time RT-PCR analysis of BAX showed that when combined with 50 μM EGCG, only 1000 μg / ml of BAX was significantly increased compared with the treatment with either agent alone. The level of apoptosis marker BAX mRNA was significantly upregulated, but this effect was not significant at a concentration lower than 1000 μg / ml in combination with 50 μM EGCG. It will not appear in .
[0116] Similarly, real-time RT-PCR analysis of BAX showed that when combined with 50 μM EGCG, only 1000 μg / ml of The composition can significantly increase the level of BAX mRNA, a marker of apoptosis.
[0117] We also detected the expression of the two markers at the protein level. As shown in the figure below, the results of Western blot analysis showed that in this study, compared with those using only Compared with the treatment with 50 μM EGCG, the concentrations of 100 to 250 μg / ml in this study The effect was maximal at this point, as 500 to 1000 μg / ml of the agent was significantly reduced compared to treatment with the agent alone. When combined with 50 μM EGCG, there was no significant reduction in PCNA protein. For BAX, compared with the treatment with the single agent, The combination with 50 μM EGCG also did not cause a significant upregulation of BAX protein levels.
[0118]
[0119]
[0120] Based on these studies, Treatment with the combination of EGCG inhibited the growth of HuLM cells due to reduced proliferation rather than increased apoptosis. Real-time RT-PCR and Western blotting data confirmed these results.
[0121] Similarly, it can be seen The combined treatment of the composition and EGCG inhibited the growth of HuLM cells by reducing proliferation. Real-time RT-PCR and Western blot data were used to confirm these results.
[0122] Materials and methods:
[0123] Reagent preparation: 250 mg The dry powder was dissolved in 50 ml of cell culture medium (DMEM / F12 containing 10% FBS) and stirred continuously at room temperature for 1 hour. Thereafter, the extract was sterile filtered through a 0.22 μm PES filter and stored at room temperature until further use. EGCG was dissolved in DMSO to make a 100 mM stock solution or dissolved in dH2O to make a 10 mM stock solution.
[0124] Cell proliferation assay:
[0125] Cell proliferation assays were performed by using the dimethylthiazolyldiphenyltetrazolium bromide (MTT) assay.
[0126] Human uterine leiomyoma (HuLM) cells were cultured in DMEM / F12 containing 10% fetal bovine serum. HuLM cells were seeded into 96-well plates at a density of 3000 cells / well and then treated with different concentrations of reagents at different time points as described in the following figures. DMSO was added as a vehicle to the control wells.
[0127] After 1 to 2 days, 3 days, 5 days, and 7 days, samples (from the treated and control wells) were measured. The medium was replaced with fresh complete medium every 48 hours. The relative cell viability was determined using the MTT assay.
[0128] At each time point, the cell supernatant was removed, 150 μl of PBS solution containing 0.5 mg / ml MTT was added to each well, and the plate was incubated at 37 °C for 4 hours. Then, it was aspirated, and 200 μl of dimethyl sulfoxide (DMSO) was added to each well and placed on a shaker and gently shaken for 15 minutes to 1 hour until the insoluble formazan was dissolved in DMSO, while avoiding light. The absorbance was measured at 570 nm in a Varioskan Lux microplate reader (ThermoFisher).
[0129] The data were expressed as the percentage of relative survival rate compared to the vehicle control group only at each time point for each drug or combination of drugs. Each data point was the mean ± SEM of 4 repeated measurements. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
[0130] Composition indicators
[0131] To determine the synergistic effect, based on the time course of single reagents and combined treatments, different dose combinations and time courses of and EGCG were selected, and the combination index (CI) scores were calculated using the Chou-Talalay method and CompuSyn software. For this analysis, we input the data of combined treatments and the data obtained from previous single reagent treatments into CompuSyn to determine the CI values at each combined point. The CI values quantitatively define antagonism (CI > 1.5), additivity (1 < CI < 1.5), and synergy (CI < 1), and the results were presented as classical isobolograms.
[0132] Western blotting:
[0133] Proteins were collected after 48 hours of treatment, extracted and lysed in RIPA buffer (Sigma) on ice. Proteins were separated in SDS-PAGE and then transferred to PVDF membranes (Bio-Rad). Blocked for one hour at room temperature with TBS-T (150mmol / L NaCl, 10mmol / L TRIS and 0.1% TWEEN-20) containing 5% skim milk, and then incubated with primary antibodies overnight at 4°C. All primary antibodies were purchased from Genetex and Abcam. The membranes were washed 3 times with TBS-T for 10 minutes each time and incubated with appropriate HRP-coupled secondary antibodies at room temperature for 1 hour. Proteins were measured using ChemiDoc (Bio-Rad). Bands were quantified using Fiji software.
[0134] Quantitative Real-Time PCR:
[0135] After 48 hours of treatment, total RNA was collected from the cells and extracted using the RNeasy Plus mini kit (Qiagen). cDNA was synthesized using SuperScript reverse transcriptase (Invitrogen) according to the manufacturer's instructions. The expression level of the target was detected using SsoAdvanced SYBR Green supermix (Bio-Rad). The primers used in this study are shown in the following table. Data were acquired as Ct values and used to determine the ΔCt value (Ct value of the target gene minus the Ct value of the internal reference gene GAPDH). These values were then used to generate the average ΔCt value ± SD for each treatment for statistical comparison. The ΔCt values were converted to fold change data relative to the ΔCt value of the vector-only control cells and the formula 2- ΔΔ Ct is calculated to enable visual representation of the data.
[0136] Target Gene sequence PCNA Forward 5'-3' GCAAGTGGAGAACTTGGAAATG Reverse 5'-3' GCCTAAGATCCTTCTTCATCCTC Bax Forward 5'-3' CCCCCGAGAGGTCTTTTTCC Reverse 5'-3' TGTCCAGCCCATGATGGTTC GAPDH Forward 5'-3' GACAGTCAGCCGCATCTTCT Reverse 5'-3' GCGCCCAATACGACCAAATC
[0137] Statistical analysis: GraphPad Prism software was used for statistical analysis, and data are presented as mean ± SD. Means of more than two groups of data were compared using two-way analysis of variance (ANOVA), followed by Tukey's test. *p<0.05, **p<0.01, ***p<0.001.
[0138] Supplementary data:
[0139] From a single experiment The results of cell viability after treatment with 50 μM EGCG for 2, 3, 5, and 7 days are shown below. The Y axis shows the relative cell viability compared to vehicle control treatment.
[0140] Individual experiment 1:
[0141]
[0142] Individual experiment 2:
[0143]
[0144] From a single experiment The synergistic effect results with 10, 25 and 50 μM EGCG treatment are shown below. The corresponding combination index (CI) data of the corresponding isobolograms are shown next to each isobologram.
[0145] Individual experiment 1:
[0146]
[0147] Individual experiment 2:
[0148]
[0149] In one embodiment, the present application discloses a study of culturing human leiomyoma cells and confirms a composition comprising and EGCG, such as ABC-105 and ABC-205, The combination of ABC-105 and EGCG showed an unexpected synergistic effect in significantly reducing the cell viability of patients with uterine fibroids. and 400mg EGCG, formulated in capsules. ABC-205 contains 920mg and 150 mg EGCG, formulated in capsules.
[0150] Likewise, The combined preparation of the composition and EGCG showed an unexpected synergistic effect in significantly reducing the cell viability of patients with uterine fibroids.
[0151] A liver safety analysis is necessary before initiating a randomized, double-blind, placebo-controlled, multicenter, prospective clinical trial of ABC-105 / ABC-205 in women with uterine fibroids to assess the size and associated symptoms of UF. Liver safety is a primary concern because treatments for uterine fibroids, primarily biologics, frequently encounter issues with liver safety. The liver safety of treatment with the combination of ABC, #imgpt218# plus EGCG is unclear. A 4-arm study could be conducted in women with uterine fibroids to allow comparison of the groups. The results of this study could be used to confirm liver safety in the larger multicenter ABC study.
[0152] Results: 30 days of treatment for patients with uterine fibroids of different stages, grades, and sizes can reduce uterine fibroids by 10% to 30%. In some studies, 60 days of treatment for patients with uterine fibroids of different sizes has been found to reduce uterine fibroids by 10% to 50%. In addition, 90 days of treatment for patients with uterine fibroids of different sizes has been found to reduce uterine fibroids by 50% to greater than 90%.
[0153] Although multiple exemplary embodiments, aspects and variations are provided herein, those skilled in the art will recognize certain modifications, permutations, additions and combinations of the embodiments, aspects and variations, as well as certain sub-combinations. It is intended that the appended claims be interpreted as including all such modifications, permutations, additions and combinations, and certain sub-combinations of the embodiments, aspects and variations are within their scope.
[0154] The entire disclosures of all documents cited in this application are incorporated herein by reference.
Claims
1. A therapeutically active composition comprising a dry extract of Crinum latifolium L. and epigallocatechin gallate (EGCG), wherein The ratio of the Crinum juncea dry extract to EGCG in the composition is in the range of 1:10 wt / wt to 100:1 wt / wt.
2. A therapeutically active composition comprising the isolated Compositions 1 to 20.
3. The method according to claim 2 comprising separating The therapeutically active composition of the composition, the isolated The composition is selected from the group consisting of: Composition 1, comprising components A , B , C , D , E , F , G , H , I , J and K ; Composition 2, comprising components A and B ; Composition 3, comprising components A , B and C ; Composition 4, comprising components A , B , C and D ; Composition 5, comprising components A and C ; Composition 6, comprising components A , C and D ; Composition 7, comprising components A , B , G and H ; Composition 8, comprising components D , E , F , G and H ; Composition 9, comprising components A , D , E , F , G and H ; Composition 10, comprising components A , F , G and H ; Composition 11, comprising components A , B , C , I , J and K ; Composition 12, comprising components C , D , E and F ; Composition 13, comprising components C , D , E , F , G , H and I ; Composition 14, comprising components D , E and F ; Composition 15, comprising components D , E , F , G and H ; Composition 16, comprising components A , D , E and F ; Composition 17, comprising components C , D , G , H and I ; Composition 18, comprising components D , E , F , J and K ; Composition 19, comprising components A , B , C , D , E , F and G ;and Composition 20, comprising components E , F , G and H .
4. The composition according to claim 1, wherein The composition The ratio to EGCG ranged from 1:1 wt / wt to 10:1 wt / wt.
5. The composition according to claim 4, wherein The composition The ratio to EGCG ranged from 1:1 wt / wt to 5:1 wt / wt.
6. The composition according to claim 4, wherein The composition The ratio to EGCG ranged from 4.0:1 wt / wt to 5.5:1 wt / wt.
7. The composition according to any one of claims 1 and claims 4 to 6, wherein and EGCG were formulated as dry powders.
8. The composition according to claim 7, wherein and EGCG are formulated in a capsule preparation or capsule dosage form.
9. A pharmaceutical composition comprising a therapeutically active composition, wherein the therapeutically active composition comprises: the dry extract of Crinum junceum of any one of claims 1 and claims 4 to 6 and a mixture of epigallocatechin gallate (EGCG); and a pharmaceutically acceptable excipient, wherein The composition is effective for treating intramural fibroids or subserosal fibroids (uterine leiomyoma).
10. A method for treating, preventing, slowing progression, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyoma) in a subject or a subject at risk of having one of the intramural or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject daily a therapeutically active composition comprising a dry extract of Crinum junceum and epigallocatechin gallate (EGCG), wherein The ratio of the Crinum chinense dry extract to EGCG in the composition is in the range of 1:10wt / wt to 100:1wt / wt, so as to prevent, slow down the progression and / or inhibit intramural fibroids or subserosal fibroids.
11. The method according to claim 10, wherein: The composition The ratio to EGCG ranged from 1:1 wt / wt to 10:1 wt / wt.
12. A method for treating, preventing, slowing progression, and reversing one or more symptoms of an intramural or subserosal fibroid (uterine leiomyoma) in a subject or a subject at risk of having one of the intramural or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject a therapeutically active composition comprising an isolated The therapeutically active composition of the composition, the isolated The composition is selected from the group consisting of: Composition 1, comprising components A , B , C , D , E , F , G , H , I , J and K ; Composition 2, comprising components A and B ; Composition 3, comprising components A , B and C ; Composition 4, comprising components A , B , C and D ; Composition 5, comprising components A and C ; Composition 6, comprising components A , C and D ; Composition 7, comprising components A , B , G and H ; Composition 8, comprising components D , E , F , G and H ; Composition 9, comprising components A , D , E , F , G and H ; Composition 10, comprising components A , F , G and H ; Composition 11, comprising components A , B , C , I , J and K ; Composition 12, comprising components C , D , E and F ; Composition 13, comprising components C , D , E , F , G , H and I ; Composition 14, comprising components D , E and F ; Composition 15, comprising components D , E , F , G and H ; Composition 16, comprising components A , D , E and F ; Composition 17, comprising components C , D , G , H and I ; Composition 18, comprising components D , E , F , J and K ; Composition 19, comprising components A , B , C , D , E , F and G ;and Composition 20, comprising components E , F , G and H ; To prevent, slow the progression and / or inhibit intramural or subserosal fibroids.
13. The method according to claims 10 to 12, wherein: and EGCG, or The composition is formulated in a capsule formulation or capsule dosage form.
14. A method of treating intramural or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject a therapeutically active composition comprising a dry extract of Crinum junceum and epigallocatechin gallate (EGCG), wherein The ratio of the dry extract of Crinum cymoides and EGCG in the composition is in the range of 1:10wt / wt to 100:1wt / wt; or administering the isolated composition.
15. The method according to claim 14, wherein: The administration of the therapeutically active composition results in significant modulation of signaling pathways involved in cell proliferation, inflammation, apoptosis, and metastasis, thereby resulting in at least one of reduction and elimination of growth of an intramural fibroid or a subserosal fibroid in the subject.
16. A method for treating, preventing, slowing progression, and reversing one or more symptoms of intramural or subserosal fibroids (uterine leiomyoma) in a subject or a subject at risk of having one of the intramural or subserosal fibroids in a subject in need thereof, the method comprising administering to the subject a therapeutically active composition comprising a dry extract of Crinum junceum and epigallocatechin gallate (EGCG), of which, The ratio of the Crinum chinense dry extract to EGCG in the composition is in the range of 1:10 wt / wt to 100:1 wt / wt, so as to prevent, slow down the progression and / or inhibit intramural fibroids or subserosal fibroids.
17. The method according to any one of claims 14 to 16, wherein: Apply the southwestern crinum dry extract and epigallocatechin gallate (EGCG), wherein the ratio of the southwestern crinum dry extract to EGCG in the composition is in the range of 1:10wt / wt to 100:1wt / wt, and wherein the administration is and concomitant administration of EGCG.
18. The method according to any one of claims 12 to 17, wherein: The dosage of was 920 mgs, two capsules twice a day, equivalent to 3680 mgs per day, for 90 days; and the dosage of EGCG was 400 mgs, one capsule twice a day, equivalent to 800 mgs per day, for 90 days.
19. The method according to any one of claims 12 to 17, wherein: The dosage of EGCG is 50 mg to 1,000 mg per day, wherein the daily dosage of EGCG is 50 mg to 1,000 mg per day. and EGCG for at least 30 days, 60 days, 90 days or 120 days.
20. A method for treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of a composition comprising an isolated Composition, the separated The composition is selected from the group consisting of: Composition 1, comprising components A , B , C , D , E , F , G , H , I , J and K ; Composition 2, comprising components A and B ; Composition 3, comprising components A , B and C ; Composition 4, comprising components A , B , C and D ; Composition 5, comprising components A and C ; Composition 6, comprising components A , C and D ; Composition 7, comprising components A , B , G and H ; Composition 8, comprising components D , E , F , G and H ; Composition 9, comprising components A , D , E , F , G and H ; Composition 10, comprising components A , F , G and H ; Composition 11, comprising components A , B , C , I , J and K ; Composition 12, comprising components C , D , E and F ; Composition 13, comprising components C , D , E , F , G , H and I ; Composition 14, comprising components D , E and F ; Composition 15, comprising components D , E , F , G and H ; Composition 16, comprising components A , D , E and F ; Composition 17, comprising components C , D , G , H and I ; Composition 18, comprising components D , E , F , J and K ; Composition 19, comprising components A , B , C , D , E , F and G ;and Composition 20, comprising components E , F , G and H , to patients who need this treatment.
21. The method according to claim 20, wherein: The cancer is selected from the group consisting of leukemia, neuroblastoma, glioblastoma, cervical cancer, colorectal cancer, pancreatic cancer, renal cancer and melanoma.
22. The method according to claim 20, wherein: The cancer is selected from the group consisting of lung cancer, breast cancer, prostate cancer, ovarian cancer, and head and neck cancer.
